Since the inception of radionuclide therapies by John Lawrence and Saul Hertz over 80 y ago, little has changed regarding ...
Radiopharmaceuticals have emerged as a transformative modality in precision oncology, with growing potential in non-oncologic ...
Radiopharmaceutical therapy (RPT) delivers protracted, low absorbed dose rate radiation over time, with cellular DNA repair ...
The Nuclear Medicine Global Initiative was formed in 2012 by 13 international organizations to promote human health by advancing the field of nuclear medicine and molecular imaging by supporting the ...
Developing novel radiopharmaceuticals for cancer theranostics has recently attracted extensive interest. Bifunctional chelators are key components of many radiometal-based radiopharmaceuticals. For ...
Journal of Nuclear Medicine August 2026, jnumed.125.271439; DOI: https://doi.org/10.2967/jnumed.125.271439 ...
Elevation of the end-tidal partial pressure of CO2 (PETco2) increases cerebral and myocardial blood flow (MBF), suggesting that it may be a suitable alternative to pharmacologic stress or exercise for ...
Journal of Nuclear Medicine May 2026, jnumed.125.271348; DOI: https://doi.org/10.2967/jnumed.125.271348 ...
WHY IS FAP-TARGETED THERAPY ATTRACTIVE? FAP-positive CAFs are found in more than 90% of epithelial cancers, therefore representing a potential pan-cancer target (6). Targeting FAP to deplete stromal ...
Real-World Outcomes of [177 Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate Cancer ...
Pulling Together: A 5-Year Plan to Improve Theranostic Outcomes by Improving the Accuracy of Dosimetry—An FNIH Joint Academic, Clinical, and Industrial Collaboration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results